• Publications
  • Influence
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
BACKGROUND The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oralExpand
  • 713
  • 16
  • PDF
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
BACKGROUND & AIMS Entecavir is a nucleoside analogue with potent in vitro activity against lamivudine-resistant hepatitis B virus (HBV). This randomized, dose-ranging, phase 2 study compared theExpand
  • 241
  • 8
1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
3. PR plus BOC for 44 weeks (BOC/PR48). Primary endpoint was SVR 24 wks post-therapy (Roche TaqMan LLD = 9.3 IU/mL). Results: SVR was numerically higher in patients with G1a (66–73%) compared to G1bExpand
  • 19